Today: 23 May 2026
Browse Category

NYSE:LLY 24 December 2025 - 3 January 2026

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly shares rose 0.5% to $1,080.36 in after-hours trading Friday after a volatile session. The move follows sector-wide drug price changes and renewed Washington scrutiny, with manufacturers planning 2026 list-price hikes. Investors are watching upcoming U.S. jobs and inflation data, as well as Lilly’s Jan. 13 conference appearance ahead of its Feb. 4 earnings report.
3 January 2026
··
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, with a median increase of about 4%, according to 3 Axis Advisors. List prices for about nine drugs will drop, including a more than 40% cut for Jardiance after Medicare negotiations. Eli Lilly faces price pressure in both the U.S. and China, where its diabetes drug Mounjaro will also get cheaper from Jan. 1.
1 January 2026
··
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly shares rose 0.2% to $1,078.73 in after-hours trading Monday, with 1.64 million shares traded. Lilly Endowment Inc. disclosed the sale of 2,629 shares at $1,085.17 each, retaining over 92 million shares. Investors focused on obesity drug pricing, with Lilly and Novo Nordisk preparing pill versions and shifting to telehealth and direct-to-consumer sales. The S&P 500 fell 0.35% and the Nasdaq lost 0.5%.
29 December 2025
··
Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly shares closed at $1,077.75, up $0.55, after ABL Bio announced it will receive $40 million upfront and a $15 million equity investment from Lilly under a research deal. The agreement follows a broader pact valued at up to $2.6 billion. Investors are watching for 2026 regulatory decisions on Lilly’s obesity drug pipeline. The S&P 500 and Dow slipped slightly on Friday.
29 December 2025
··
Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly shares closed at $1,077.75 Friday, near record highs, as U.S. markets shut for the weekend. ABL Bio announced $55 million in new funding tied to Lilly, including a $40 million upfront payment and $15 million equity investment. Investors remain focused on obesity-drug momentum and the FDA’s recent approval of Novo Nordisk’s weight-loss pill.
28 December 2025
·
Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly shares closed near record highs Friday at $1,077.75, with trading volume muted ahead of the weekend. ABL Bio announced it expects a $40 million upfront payment and $15 million equity investment from Lilly tied to their Grabody platform collaboration. The deal targets obesity and muscle diseases. Novo Nordisk’s oral Wegovy approval this week intensified competition in the obesity drug market.
28 December 2025
··
Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly shares ended Friday at $1,077.75, near record highs, as the market weighed strong demand for obesity drugs against rising pricing and access pressures. Novo Nordisk’s FDA approval for an oral Wegovy pill this week put pressure on Lilly, whose own oral therapy is expected in 2026. The stock’s equity value remains around $1 trillion. U.S. markets reopen Monday, with traders watching for weekend developments.
27 December 2025
·
Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly shares closed Friday near $1,077.75, little changed after a narrow session. The Centers for Medicare & Medicaid Services this week announced a plan to expand GLP‑1 drug access, capping monthly costs at $50 for Medicare beneficiaries. A Trump-era pricing deal also sets lower reference prices for weight-loss drugs. Investors are watching policy shifts as key drivers for LLY’s valuation.
27 December 2025
··
Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly shares traded near $1,075 Friday afternoon, down 0.2% in thin post-Christmas trading as U.S. indexes hovered close to record highs. The stock moved between $1,068 and $1,082 amid muted volume. The NYSE and Nasdaq remained open for a regular session. Investors continue to watch Lilly’s pricing moves and its lead in obesity and diabetes treatments.
26 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly stock last traded at $1,076.98 before the holiday break, with after-hours pricing at $1,077.97. Trading resumes Friday amid new U.S. policy moves to expand GLP-1 drug coverage and push prices lower, including a CMS model and TrumpRx pricing plan. Investors are watching for price swings as thinner holiday-week liquidity meets headline risk.
26 December 2025
··
Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly shares closed at $1,076.98 after the early NYSE close on Dec. 24, with after-hours quotes near $1,077–$1,078 in thin holiday trading. U.S. exchanges remained shut Dec. 25 for Christmas. The 52-week range stands at $623.78 to $1,111.99. Trading volume is expected to rise when markets reopen Friday, with attention on GLP-1 policy and competition.
25 December 2025
·
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly shares closed up 0.50% at $1,076.98 in light Christmas Eve trading, then slipped to $1,071.74 after hours amid thin volume. The move followed news that U.S. regulators plan to expand Medicaid and Medicare coverage for GLP‑1 obesity drugs, including Lilly’s Zepbound, with a $50 monthly cap for Medicare starting January 2027.
24 December 2025
···
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly shares rose 0.47% to $1,076.67 in light Christmas Eve trading, with volume just over 200,000 shares by late morning. Investors focused on new GLP-1 headlines, including regulatory updates and global expansion, as well as a Reuters report showing Lilly’s Mounjaro outpacing Novo’s Wegovy in India since March. Indian generics are expected to intensify competition as patent expiries approach.
24 December 2025
···
1 … 5 6 7 8 9 … 12

Stock Market Today

  • ZKH Group Q1 2026 Loss Narrows to C¥10.1m Amid Mixed Profitability Signals
    May 23, 2026, 6:14 AM EDT. ZKH Group (NYSE:ZKH) reported Q1 2026 revenue of C¥2.1 billion and a basic EPS loss of C¥0.06. Trailing 12-month figures show a net loss narrowing to C¥83.1 million from C¥268 million in Q4 2024, with revenue stable near C¥9.2 billion. Improvements link to higher private label mix and AI efficiencies, supporting a 43.9% multi-year earnings growth rate despite continued losses. Earnings per share have fluctuated, with concerns over volatility and fragile profitability. Bears highlight narrow quarterly profits and persistent trailing losses as risks, with a low price-to-sales ratio of 0.3x versus industry peers and a significant gap to a discounted cash flow fair value of US$15.27, suggesting the stock may be undervalued but exposed to execution risks.

Latest articles

Gold Price Near $4,830 Faces Monday Test After Hormuz Reversal Revives Safe-Haven Risk

Gold Watch: $4,500 Level in Focus for Next Move

23 May 2026
Gold ended Friday at $4,508.50 an ounce, down 0.74% for the day and logging a second weekly drop as renewed Fed rate-hike bets and oil-driven inflation fears weighed on prices. Spot silver fell 1.52%, platinum 2.49%, and palladium 2.98%. U.S. markets face a holiday-shortened week ahead, with Memorial Day closures on Monday. Physical demand in India and China remained weak amid Fed anxiety and a strong dollar.
XRP ETFs Hit $1.53 Billion as Bitwise Pulls Ahead, but the Chart Has a Catch

XRP in Focus After Weekend Pullback; Traders Watch $1.30 as ETF Flows Stay Strong

23 May 2026
XRP dropped to $1.31 Saturday, down 3.9% in 24 hours and 7.4% over seven days, underperforming the broader crypto market. Trading volume reached $2.16 billion, with a market value near $81 billion. U.S. equity and listed crypto products will remain closed for Memorial Day on May 25. The SEC’s case against Ripple Labs ended in August 2025 with a $125 million fine and an injunction on institutional XRP sales.
Bitcoin Price Today Slips Below $70,000 as CPI Looms and Iran Risks Keep Traders on Edge

Bitcoin could test $75,000 as markets look ahead to Wall Street reopening

23 May 2026
Bitcoin fell to $74,594 on Saturday, down 3.3% after U.S. spot bitcoin ETFs saw five straight days of outflows. Ether dropped 4.3% to $2,026.64. The decline came as U.S. markets closed for the holiday weekend and bond yields hit multi-year highs. Coinbase shares closed Friday at $184.99, down 4.4%.
Go toTop